Clinical Trial Update: The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating whole-body 124I-PET/CT dosimetry in patients with differentiated thyroid cancer; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer

Drugs mentioned

• Iodine-124 (Iodine-124)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Thyroid Cancer | Phase 2 | Status: RECRUITING